Theravance Biopharma (TBPH) stock price, revenue, and financials

Theravance Biopharma market cap is $1.3 b, and annual revenue was $60.37 m in FY 2018

$1.3 B

TBPH Mkt cap, 27-Mar-2020

$60.4 M

Theravance Biopharma Revenue FY, 2018
Theravance Biopharma Revenue growth (FY, 2017 - FY, 2018), %292%
Theravance Biopharma Gross profit (FY, 2018)59.7 M
Theravance Biopharma Gross profit margin (FY, 2018), %98.8%
Theravance Biopharma Net income (FY, 2018)-215.5 M
Theravance Biopharma EBIT (FY, 2018)-238.8 M
Theravance Biopharma Cash, 31-Dec-2018378 M
Theravance Biopharma EV1.2 B

Theravance Biopharma Revenue

Theravance Biopharma revenue was $60.37 m in FY, 2018 which is a 292.4% year over year increase from the previous period.

Embed Graph

Theravance Biopharma Revenue Breakdown

Embed Graph

Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other

Theravance Biopharma Income Statement

Theravance Biopharma Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018

Cash

344.7m89.0m378.0m

Accounts Receivable

646.0k2.3m620.0k

Inventories

12.2m16.8m

Current Assets

528.5m378.7m532.8m

PP&E

8.5m10.2m13.2m

Total Assets

639.3m441.4m560.2m

Accounts Payable

1.7m5.9m9.0m

Current Liabilities

49.3m62.6m98.6m

Long-term debt

222.7m223.7m224.8m

Non-Current Liabilities

239.8m263.7m513.3m

Total Debt

222.7m223.7m224.8m

Common Stock

1.0k1.0k1.0k

Additional Paid-in Capital

862.7m913.7m960.7m

Retained Earnings

(512.2m)(797.7m)(1.0b)

Total Equity

350.2m115.2m(51.6m)

Debt to Equity Ratio

0.6 x1.9 x-4.4 x

Debt to Assets Ratio

0.3 x0.5 x0.4 x

Financial Leverage

1.8 x3.8 x-10.9 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

128.8m148.4m86.6m169.9m139.6m91.3m125.8m103.9m101.2m

Accounts Receivable

1.5m1.9m873.0k1.2m1.3m1.6m2.0m3.4m3.0m

Inventories

9.4m9.8m12.5m13.2m12.1m15.3m17.2m17.9m17.9m

Current Assets

238.8m303.1m274.0m421.5m384.9m367.1m446.8m386.7m332.6m

PP&E

10.1m8.8m8.8m8.3m8.7m8.6m10.3m10.7m12.4m

Total Assets

293.1m374.5m356.3m588.0m543.9m486.2m480.1m421.4m371.0m

Accounts Payable

9.1m7.4m5.4m3.6m6.4m5.6m5.1m3.6m3.7m

Current Liabilities

46.4m44.7m45.4m49.0m57.1m48.8m105.2m93.5m102.0m

Long-term debt

222.9m223.2m223.5m224.0m224.3m224.6m

Non-Current Liabilities

8.2m8.2m13.0m245.1m245.7m251.3m311.5m293.5m282.4m

Total Debt

222.9m223.2m223.5m224.0m224.3m224.6m

Common Stock

1.0k1.0k1.0k1.0k1.0k1.0k

Additional Paid-in Capital

602.1m732.3m742.7m871.9m885.3m895.2m926.0m937.4m948.8m

Retained Earnings

(363.7m)(410.9m)(444.9m)(577.7m)(643.9m)(710.8m)(861.7m)(902.5m)(962.0m)

Total Equity

238.5m321.6m297.9m293.9m241.1m184.1m63.4m34.4m(13.4m)

Debt to Equity Ratio

0.8 x0.9 x1.2 x3.5 x6.5 x-16.7 x

Debt to Assets Ratio

0.4 x0.4 x0.5 x0.5 x0.5 x0.6 x

Financial Leverage

1.2 x1.2 x1.2 x2 x2.3 x2.6 x7.6 x12.3 x-27.6 x

Theravance Biopharma Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

(190.7m)(285.4m)(215.5m)

Depreciation and Amortization

3.1m4.0m3.2m

Accounts Receivable

1.3m(1.6m)1.6m

Inventories

(3.2m)(7.3m)(1.6m)

Accounts Payable

(16.4m)3.8m3.6m

Cash From Operating Activities

(99.0m)(201.1m)(112.9m)

Purchases of PP&E

(2.1m)(2.4m)(7.2m)

Cash From Investing Activities

(2.1m)(2.4m)(7.2m)

Cash From Financing Activities

479.2m1.7m225.2m

Net Change in Cash

232.0m(255.7m)289.0m

Interest Paid

7.5m7.5m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(42.1m)(89.4m)(123.3m)(65.3m)(131.6m)(198.5m)(65.1m)(105.9m)(165.3m)

Depreciation and Amortization

699.0k1.2m1.9m1.1m2.1m3.0m900.0k1.7m2.3m

Accounts Receivable

395.0k66.0k1.0m(587.0k)(700.0k)(930.0k)280.0k(1.2m)(771.0k)

Inventories

134.0k157.0k(1.8m)140.0k(497.0k)(3.0m)(371.0k)(351.0k)(552.0k)

Accounts Payable

(9.4m)(10.8m)(12.8m)2.0m4.8m3.5m(449.0k)(2.3m)(1.7m)

Cash From Operating Activities

(26.3m)(58.4m)(70.9m)(50.0m)(94.6m)(156.8m)49.8m(11.7m)(60.7m)

Purchases of PP&E

(684.0k)(1.3m)(1.7m)(587.0k)(1.3m)(2.2m)(2.8m)(3.9m)(5.7m)

Cash From Investing Activities

16.4m(52.2m)(102.0m)(123.5m)(112.3m)(97.6m)(11.3m)30.7m77.3m

Cash From Financing Activities

26.0m146.3m146.8m(1.2m)1.8m1.0m(1.7m)(4.1m)(4.4m)

Net Change in Cash

16.1m35.7m(26.1m)(174.8m)(205.1m)(253.4m)36.9m14.9m12.2m

Interest Paid

3.7m3.7m3.7m3.7m

Theravance Biopharma Ratios

USDY, 2018

EV/EBIT

-4.9 x

EV/CFO

-10.4 x

Debt/Equity

-4.4 x

Debt/Assets

0.4 x

Financial Leverage

-10.9 x

Theravance Biopharma Operating Metrics

FY, 2016FY, 2017FY, 2018Apr, 2019

Partners

6

Patents (Foreign)

1.68 k1.96 k1.67 k

Patents (US)

434 459 438